低分子肝素治疗急性缺血性脑卒中的临床疗效观察

Low Molecular Weight Heparin in the Treatment of Acute Cerebal Infarction

目的评价低分子肝素(LMWH)治疗急性缺血性脑卒中的有效性及安全性。方法85例急性缺血性脑卒中患者随机分为治疗组(n=45)和对照组(n=40)。治疗组给予LMWH,对照组给予低分子右旋糖酐及丹参,疗程均为11天。结果治疗组显效率为88.6%,对照组为45%,两组相比差异显著(P<0.01)。治疗组治疗后与治疗前相比,神经功能缺损评分明显改善(P<0.01),但出凝血时间、白陶土部分凝血活酶时间、血小板计数等实验室检查指标无明显变化。结论LMWH治疗急性缺血性脑卒中疗效明确,安全可靠。

Objective To evaluate the efficacy and safety of low molecular weight heparin in the treatment of acute cerebal infarction. Methods 85 patients with acute cerebal infarction were randomly assigned to the treatment group（n=45） and the control group（n=40） .The treatment group was administrated low molecular weight heparin and the control group was administrated dextran 40 plused salvia miltiorrhiza injection. Results The noted effective rate of the treatment group was significantly higher than that of the control group（88.6% vs 45%, P〈0.01）.The laboratory tests such as blood platelets count and kaolin partial thromboplastin time have no difference in both groups before and after treatment. Conclusion Low molecular weight heparin can be ued in the treatment of acute cerebal infarction effectively and safely.